REFERENCES
- Fuchs AR, Romero R, Keefe D, Parra M, Oyarzun E, Behnke E. Oxytocin secretion and human parturition: Pulse frequence and duration increased during spontaneous labor in women. Am J Obstet Gynecol 1991;165:1515–1523.
- Lefebvre DL, Giaid A, Bennett H, Lariviere R, Zingg HH. Oxytocin gene expression in rat uterus. Science 1992;256: 1553–1555.
- Chibbar R, Miller FD, Mitchell BF. Synthesis of oxytocin in amnion, chorion and decidua may influence the timing of human parturition. J Chin Invest 1993;91:185–192.
- Maggi M, Del Carlo P, Fantoni G, et al. Human myometrium during pregnancy contains and respond to VI VP receptors as well as oxytocin receptors. J Clin Endocrinol Metab 1990;70:1142–1154.
- Bossmar T, Akerlund M, Fantoni G, Szamatowicz J, Melin P, Maggi M. Receptors for and myometrial responses to oxytocin and vasopressin in preterm and term human myometrium. Effects of the antagonist Atosiban. Am J Obstet Gynecol 1994;171:1634–1642.
- Chard T, Hudson CN, Edwards CRW, Boyd NHR. Release of oxytocin and vasopressin by the human foetus during labour. Nature 1971;234:352–354.
- Akerlund M, Brouard R, Bossmar T, et al. Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women. Br J Obstet Gynaecol 1999;106:1047–1053.
- Akerlund M, Stromberg P, Hauksson A, et al. Inhibition of uterine contractions of premature labour with an oxytocin analogue. Results from a pilot study. Br J Obstet Gynaecol 1987;94:1040–1044.
- Goodwin TM, Paul R, Silver H, et al. The effects of the oxytocin antagonist atosiban on preterm uterine activity in the human. Am J Obstet Gynecol 1994;170:474–478.
- Romero R, Sibai BM, Sanchez-Ramos L, et al. An oxytocin receptor antagonist (Atosiban) in the treatment of preterm labor: A randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol 2000;182:1173–1183.
- Worldwide Atosiban versus /3-Agonist Study Group. An analysis of the pooled data from three randomised double-blind controlled trials of the oxytocin antagonist atosiban versus the /3-adrenergic agonists ritodrine, terbutaline and salbutamol in the treatment of preterm labour. Br J Obstet Gynaecol 2001;108: 133–142.
- Bossmar T, Brouard R, Döberl A, Akerlund M. Effects of SR 49059, an orally active vasopressin Via receptor antagonist on vasopressin-induced uterine contractions in women. Br J Obstet Gynaecol 1997;104: 471–477.
- Brouard R, Bossmar T, Fournie-Lloret D, Chassard D, Akerlund M. Effect of SR 49059, an orally active vasopressin Via receptor antagonist, in the prevention of dysmenorrhoea. Br J Obstet Gynaecol 2000;107: 614–618.
- Akerlund M, Andersson K-E, Ingemarsson I. Effects of terbutaline on myometrial activity, endometrial blood-flow, and lower abdominal pain in women with primary dysmenor-rhoea. Br J Obstet Gynaecol 1976;83:673–678.
- Akerlund M, Stromberg P, Forsling M-L. Primary dysmenor-rhoea and vasopressin. Br J Obstet Gynaecol 1979;86: 484–487.
- Ekström P, Laudanski T, Mrugacz G, Forsling M, Kindahl H, Akerlund M. Stimulation of vasopressin release in women with primary dysmenorrhoea and after oral contraceptive treatment - effect on uterine contractility. Br J Obstet Gynaecol 1992;99:680–684.
- Steinwall M, Bossmar T, Gaud C, Akerlund M. Inhibitory effect of SR 49059 on oxytocin- and vasopressin-induced uterine contractions in non-pregnant women. Acta Obstet Gynecol Scand 2003;82:1–7.
- Thibonnier M, Kilani A, Rahman M, etal. Effects of the non-peptide V (1) vasopressin receptor antagonist, SR 49059, in hypertensive patients. Hypertension 1999;34:1293–1300.
- Cowley AW Jr, Switzer SJ, Guinn MM. Evidence and quantification of the vasopressin arterial pressure control system in the dog. Circ Res 1980;46:58–67.
- McCombs J. Update on tocolytic therapy. Ann Pharmacother 1995;29:515–522.